Cargando…
In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019
The Antimicrobial Testing Leadership and Surveillance (ATLAS) global surveillance program collected clinical isolates of Enterobacterales (n = 8416) and Pseudomonas aeruginosa (n = 2521) from 41 medical centers in 10 Latin American countries from 2017 to 2019. In vitro activities of ceftazidime-avib...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392196/ https://www.ncbi.nlm.nih.gov/pubmed/34774471 http://dx.doi.org/10.1016/j.bjid.2021.101647 |
_version_ | 1784771012576935936 |
---|---|
author | Karlowsky, James A. Kazmierczak, Krystyna M. Valente, Maria Lavínea Novis de Figueiredo Luengas, Elkin Lemos Baudrit, Monique Quintana, Alvaro Irani, Paurus Stone, Gregory G. Sahm, Daniel F. |
author_facet | Karlowsky, James A. Kazmierczak, Krystyna M. Valente, Maria Lavínea Novis de Figueiredo Luengas, Elkin Lemos Baudrit, Monique Quintana, Alvaro Irani, Paurus Stone, Gregory G. Sahm, Daniel F. |
author_sort | Karlowsky, James A. |
collection | PubMed |
description | The Antimicrobial Testing Leadership and Surveillance (ATLAS) global surveillance program collected clinical isolates of Enterobacterales (n = 8416) and Pseudomonas aeruginosa (n = 2521) from 41 medical centers in 10 Latin American countries from 2017 to 2019. In vitro activities of ceftazidime-avibactam and comparators were determined using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method. Overall, 98.1% of Enterobacterales and 86.9% of P. aeruginosa isolates were susceptible to ceftazidime-avibactam. When isolates were analyzed by country of origin, susceptibility to ceftazidime-avibactam for Enterobacterales ranged from 97.8% to 100% for nine of 10 countries (except Guatemala, 86.3% susceptible) and from 75.9% to 98.4% for P. aeruginosa in all 10 countries. For Enterobacterales, 100% of AmpC-positive, ESBL- and AmpC-positive, GES-type carbapenemase-positive, and OXA-48-like-positive isolates were ceftazidime-avibactam-susceptible as were 99.8%, 91.8%, and 74.7% of ESBL-positive, multidrug-resistant (MDR), and meropenem-nonsusceptible isolates. Among meropenem-nonsusceptible isolates of Enterobacterales, 24.4% (139/570) carried a metallo-β-lactamase (MBL); 83.3% of the remaining meropenem-nonsusceptible isolates carried another class of carbapenemase and 99.4% of those isolates were ceftazidime-avibactam-susceptible. Among meropenem-non-susceptible isolates of P. aeruginosa (n = 835), 25.6% carried MBLs; no acquired β-lactamase was identified in the majority of isolates (64.8%; 87.2% of those isolates were ceftazidime-avibactam-susceptible). Overall, clinical isolates of Enterobacterales collected in Latin America from 2017 to 2019 were highly susceptible to ceftazidime-avibactam, including isolates carrying ESBLs, AmpCs, and KPCs. Country-specific variation in susceptibility to ceftazidime-avibactam was more common among isolates of P. aeruginosa than Enterobacterales. The frequency of MBL-producers among Enterobacterales from Latin America was low (1.7% of all isolates; 146/8,416), but higher than reported in previous surveillance studies. |
format | Online Article Text |
id | pubmed-9392196 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-93921962022-08-23 In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019 Karlowsky, James A. Kazmierczak, Krystyna M. Valente, Maria Lavínea Novis de Figueiredo Luengas, Elkin Lemos Baudrit, Monique Quintana, Alvaro Irani, Paurus Stone, Gregory G. Sahm, Daniel F. Braz J Infect Dis Original Article The Antimicrobial Testing Leadership and Surveillance (ATLAS) global surveillance program collected clinical isolates of Enterobacterales (n = 8416) and Pseudomonas aeruginosa (n = 2521) from 41 medical centers in 10 Latin American countries from 2017 to 2019. In vitro activities of ceftazidime-avibactam and comparators were determined using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method. Overall, 98.1% of Enterobacterales and 86.9% of P. aeruginosa isolates were susceptible to ceftazidime-avibactam. When isolates were analyzed by country of origin, susceptibility to ceftazidime-avibactam for Enterobacterales ranged from 97.8% to 100% for nine of 10 countries (except Guatemala, 86.3% susceptible) and from 75.9% to 98.4% for P. aeruginosa in all 10 countries. For Enterobacterales, 100% of AmpC-positive, ESBL- and AmpC-positive, GES-type carbapenemase-positive, and OXA-48-like-positive isolates were ceftazidime-avibactam-susceptible as were 99.8%, 91.8%, and 74.7% of ESBL-positive, multidrug-resistant (MDR), and meropenem-nonsusceptible isolates. Among meropenem-nonsusceptible isolates of Enterobacterales, 24.4% (139/570) carried a metallo-β-lactamase (MBL); 83.3% of the remaining meropenem-nonsusceptible isolates carried another class of carbapenemase and 99.4% of those isolates were ceftazidime-avibactam-susceptible. Among meropenem-non-susceptible isolates of P. aeruginosa (n = 835), 25.6% carried MBLs; no acquired β-lactamase was identified in the majority of isolates (64.8%; 87.2% of those isolates were ceftazidime-avibactam-susceptible). Overall, clinical isolates of Enterobacterales collected in Latin America from 2017 to 2019 were highly susceptible to ceftazidime-avibactam, including isolates carrying ESBLs, AmpCs, and KPCs. Country-specific variation in susceptibility to ceftazidime-avibactam was more common among isolates of P. aeruginosa than Enterobacterales. The frequency of MBL-producers among Enterobacterales from Latin America was low (1.7% of all isolates; 146/8,416), but higher than reported in previous surveillance studies. Elsevier 2021-11-10 /pmc/articles/PMC9392196/ /pubmed/34774471 http://dx.doi.org/10.1016/j.bjid.2021.101647 Text en © 2021 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Karlowsky, James A. Kazmierczak, Krystyna M. Valente, Maria Lavínea Novis de Figueiredo Luengas, Elkin Lemos Baudrit, Monique Quintana, Alvaro Irani, Paurus Stone, Gregory G. Sahm, Daniel F. In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019 |
title | In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019 |
title_full | In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019 |
title_fullStr | In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019 |
title_full_unstemmed | In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019 |
title_short | In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019 |
title_sort | in vitro activity of ceftazidime-avibactam against enterobacterales and pseudomonas aeruginosa isolates collected in latin america as part of the atlas global surveillance program, 2017–2019 |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392196/ https://www.ncbi.nlm.nih.gov/pubmed/34774471 http://dx.doi.org/10.1016/j.bjid.2021.101647 |
work_keys_str_mv | AT karlowskyjamesa invitroactivityofceftazidimeavibactamagainstenterobacteralesandpseudomonasaeruginosaisolatescollectedinlatinamericaaspartoftheatlasglobalsurveillanceprogram20172019 AT kazmierczakkrystynam invitroactivityofceftazidimeavibactamagainstenterobacteralesandpseudomonasaeruginosaisolatescollectedinlatinamericaaspartoftheatlasglobalsurveillanceprogram20172019 AT valentemarialavineanovisdefigueiredo invitroactivityofceftazidimeavibactamagainstenterobacteralesandpseudomonasaeruginosaisolatescollectedinlatinamericaaspartoftheatlasglobalsurveillanceprogram20172019 AT luengaselkinlemos invitroactivityofceftazidimeavibactamagainstenterobacteralesandpseudomonasaeruginosaisolatescollectedinlatinamericaaspartoftheatlasglobalsurveillanceprogram20172019 AT baudritmonique invitroactivityofceftazidimeavibactamagainstenterobacteralesandpseudomonasaeruginosaisolatescollectedinlatinamericaaspartoftheatlasglobalsurveillanceprogram20172019 AT quintanaalvaro invitroactivityofceftazidimeavibactamagainstenterobacteralesandpseudomonasaeruginosaisolatescollectedinlatinamericaaspartoftheatlasglobalsurveillanceprogram20172019 AT iranipaurus invitroactivityofceftazidimeavibactamagainstenterobacteralesandpseudomonasaeruginosaisolatescollectedinlatinamericaaspartoftheatlasglobalsurveillanceprogram20172019 AT stonegregoryg invitroactivityofceftazidimeavibactamagainstenterobacteralesandpseudomonasaeruginosaisolatescollectedinlatinamericaaspartoftheatlasglobalsurveillanceprogram20172019 AT sahmdanielf invitroactivityofceftazidimeavibactamagainstenterobacteralesandpseudomonasaeruginosaisolatescollectedinlatinamericaaspartoftheatlasglobalsurveillanceprogram20172019 |